PIK3CA and adenocarcinoma: A large study of 1144 consecutive NSCLC patients investigated tumor tissue using next generation sequencing (NGS) for PIK3CA mutations.37 Mutations were identified in 3.7% of patients, with predominance for squamous cell carcinoma (8.9%) compared with adenocarcinoma (2.9%).